Biom Therapeutics Revenue

Pharmaceutical Manufacturing • Sarasota, Florida, United States • 1-10 Employees

Biom Therapeutics revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$273,776
Total funding	No funding

Key Contact at Biom Therapeutics

Bobban Subhadra

Chief Executive Officer

Company overview

Headquarters	2203 Industrial Blvd, Sarasota, Florida 34234, US
Phone number	+19415528417
Website	biomtherapeutics.com
NAICS	3254
Keywords	Drug Development, Angelman Syndrome, Clinical Stage Biopharmaceutical, Pediatrics Epilepsy
Founded	2020
Employees	1-10
Socials

Biom Therapeutics Email Formats

Biom Therapeutics uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@biomtherapeutics.com), used 100% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@biomtherapeutics.com	100%

About Biom Therapeutics

Biom Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for brain disorders. Our mission is to improve human health and quality of life by developing innovative drugs for treating and possibly reversing the effects of hard-to-treat diseases such as rare epilepsies, Alzheimer’s disease and Autism. Biom’s initial focus is on rare pediatric epilepsy such as developmental and epileptic encephalopathies and Angelman syndrome. Dr. Paul Carney, a tenured professor at Missouri University’s School of Medicine, is a board-certified pediatric neurologist and an expert on CBD’s benefits in treating epilepsy. Building on research he conducted with grants from the state of Florida and the Angelman Syndrome Foundation, Dr. Carney, together with Bobban Subhadra, Ph.D., a drug-discovery and product-development scientist, founded the Company in 2020 to create effective treatments for neurological disorders. The Company’s lead drug candidate, BIO017, is a cannabidiol (CBD) formulation designed to treat Angelman Syndrome (AS), a genetic, neurological disorder that results in development delays, speech and movement problems, sleep difficulties, and severe seizures. Biom therapeutics has recently applied for Orphan Drug Designation (ODD) for BIO017 from FDA.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

Biom Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Biom Therapeutics has never raised funding before.

Biom Therapeutics Tech Stack

Discover the technologies and tools that power Biom Therapeutics's digital infrastructure, from frameworks to analytics platforms.

SiteGround

Hosting

Vimeo

Video players

Swiper

JavaScript libraries

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Bootstrap

UI frameworks

Yoast SEO

SEO

Google Tag Manager

Tag managers

Frequently asked questions

Biom Therapeutics is located in Sarasota, Florida, US.

You can reach Biom Therapeutics at +19415528417.

Biom Therapeutics generates an estimated annual revenue of $85,555. This revenue figure reflects the company's market position and business performance in its industry.

Biom Therapeutics has an estimated valuation of $273,776. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Biom Therapeutics was founded in 2020, making it 6 years old. The company has established itself as a significant player in its industry over this time.

Biom Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Biom Therapeutics

Bobban Subhadra

Chief Executive Officer

4.8

40,000 users